Monocl News

  • Monocl Strategy Services investerar i BioStock för att gemensamt bilda Nordens ledande analyshus inom Life Science

    7 November, 2016

    GÖTEBORG, SVERIGE, 7 NOVEMBER 2016. Monocl Strategy Services AB blir delägare i nyhets- och analystjänsten BioStock. Investeringen kompletterar Monocl Strategy Services kunderbjudande gentemot börsnoterade bolag och syftar till att tillsammans med BioStock etablera Nordens ledande analyshus inom Life Science. Monocl Strategy Services har arbetat tillsammans med BioStock sedan hösten 2015 och väljer nu att fördjupa samarbetet i form av ett

    Read more
  • Multiple myeloma – a rare disease, yet one of the most common blood cancers in the world

    12 January, 2016

    This blog post is also available as a downloadable PDF here: Monocl_MM_blog_11 Jan_2016 Multiple myeloma is the third most common blood cancer, primarily affecting elderly patients. In the last decades, major advances have been made in how the disease is managed using stem cell transplants and novel chemotherapies. However, large unmet medical needs still exist as the disease invariably relapses and patients

    Read more
  • Wearables, home testing and e-health trends

    1 November, 2015

    Wearable technology is widely expected to revolutionize healthcare, not just fitness. Earlier this year, Forbes reported that investors will commit more than $1 billion in wearable technology startup companies before year end and that the market will gross almost $2 billion in revenues next year. So far, the mainstay of wearable technology has been centered around wearable trackers for consumer fitness. With increased consumer awareness of the dangers of a sedentary lifestyle, a demand has emerged for simple, easy-to-use trackers that help people track and measure their personal health goals. Fewer and fewer people are hitting the tracks without their smart watches, phones or

    Read more
  • Osteosarcoma – a rare disease in need of new treatments

    15 July, 2015

    Osteosarcoma is a primary cancer bone tumor commonly diagnosed in patients with growing bones. Thus, the disease is most common in adolescents under an age of 30 and about 1000 individuals in Europe and the USA are diagnosed with the disease each year. Tremendous improvements of osteosarcoma treatment have occurred since 1960 including the introduction of chemotherapies, such as the use

    Read more
  • CRC – a crowded space with strong market leaders

    1 July, 2015

    Colorectal cancer (CRC) is the third most common cancer in men and the second in women worldwide, making it the third largest cancer type in the world (based on annual cases). Based on the pure market size, CRC is a lucrative opportunity, which attracts many new pharmaceutical companies and candidates. However, CRC is a crowded market and the established branded drugs – primarily Avastin and Erbitux – have established a dominance that is hard to challenge. Biosimilar

    Read more
  • Animal health – a growing market

    16 June, 2015

    Last year was a record year at the European Medicines Agency’s Committee for Medicinal Products for Veterinary Use (CVMP). During the year, the CVMP received the highest number of requests in a year (29) for the classification of veterinary medicines intended for minor use minor species (MUMS)/limited market. Twenty new veterinary medicines were recommended for marketing authorisation and an increasing number of Monocl’s

    Read more
  • Anti-CD19 drugs for targeting cancer with the body’s own disease-fighting immune cells

    23 March, 2015

    Many of our clients are interested in the immuno-oncology field and we have covered the immune checkpoint inhibitor field in the past. However, last year another immune-oncology type – other than the much covered PD-1 drugs – also reached approval. Amgen’s lightning-fast approval for Blincyto (blinatumomab) marks the first time a CD19 drug gets the nod from FDA, which it did for Acute Lymphoblastic Leukemia

    Read more
  • Novartis gets landmark biosimilar approval in the U.S. – the dawn of a new era?

    9 March, 2015

    Last week Novartis was granted an approval by the F.D.A for its biosimilar (Zarxio) version of Amgen’s immune boosting drug Neupogen, for all the five indications granted to the original drug. Thereby, Novartis is the first company to receive an approval for a “copy” of a biologics drug in the U.S., after years of debate about the introduction of biosimilars. Monocl

    Read more
  • 2015 set to be a revolutionary year for e-health in the UK

    4 March, 2015

    This week, Monocl visited the UK e-Health week in Olympia, London to follow the latest trends in the e-Health space. As most of you know, we have a particular interest in this space since we’re developing a Bio-IT tool called Monocl EGO and we believe that the current transformation (and integration) that is ongoing in the Life Science and IT-space is very exciting.   UK

    Read more
  • 2014 – a record year of drug approvals

    2 March, 2015

    This year has come to a flying start with five EPAR authorisations by the European Medicines Agency (EMA) of which two (within Idiopathic Pulmonary Fibrosis and Gaucher Disease) now enjoy orphan protection.

    Read more
  • Monocl Software awarded 2.7 MSEK from Sweden’s innovation agency VINNOVA

    25 November, 2014

    GÖTEBORG, SWEDEN, November 25, 2014. Monocl Software, a Life Science Intelligence company, has been awarded 2.7 MSEK through VINNOVA’s ‘Forska&Väx’ program. The funding will be used to enable a successful launch of MONOCL EGO in 2015. MONOCL EGO is a groundbreaking expert analytics tool designed to help professional users to find, assess and engage with relevant Life Science experts and

    Read more
  • Monocl supports MSF in the fight against Ebola

    21 October, 2014

    If contracted, Ebola is one of the world’s most deadly diseases. It is a highly infectious virus that can kill up to 90 percent of the people who catch it, causing terror among infected communities. Medecins Sans Frontieres (Läkare Utan Gränser) does a heroic job in treating hundreds of people with the disease and Monocl has therefore chosen to make

    Read more
  • Monocl Software and Petter Eriksson in Life Science Sweden [Swedish article]

    2 October, 2014

    News about Monocl Software’s latest Board appointment was today published in Life Science Sweden (LINK). Petter Eriksson ska stödja företaget i lanseringen av sitt nya verktyg för uppsökning av forskningsexperter. Petter Eriksson stärker strategikonsultbolaget Monocls styrelse.I dagsläget är han utvecklingschef på it-företaget Recorded Future och han har sedan tidigare erfarenhet från ledande tjänster på företag som Streamserve och dess uppköpare Open Text. Innan dess

    Read more
  • Monocl Software appoints Petter Eriksson to the Board of Directors

    2 October, 2014

    GÖTEBORG, SWEDEN, October 2, 2014. Monocl Software, a Life Science Intelligence company, announces the appointment of Petter Eriksson, VP of Engineering at Recorded Future, as its most recent Board member. Petter Eriksson brings highly relevant, in-depth software development expertise to the company.   Petter Eriksson is currently the VP of Engineering at Recorded Future, a web intelligence company based in US and

    Read more
  • Monocl appoints Jarl Ulf Jungnelius to the Board of Directors

    3 July, 2014

    GÖTEBORG, SWEDEN, July 3, 2014. Monocl, a leading Life Science Intelligence group, announces the appointment of Jarl Ulf Jungnelius, MD and oncologist, as its most recent Board member. Jarl Ulf Jungnelius is a seasoned Life Science executive with an impressive drug development track record and brings valuable competence to Monocl.  Jarl Ulf Jungnelius is the former Vice President CR&D Oncology

    Read more
Load More